• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Jeff Patton Discusses CMS' Proposal to Ease Protections on 6 Drug Classes in Part D

Video

Jeff Patton, MD, chief executive officer of Tennessee Oncology, offers his reaction to CMS' proposal to ease restrictions on how Part D managed the 6 protected classes of drugs.

Jeff Patton, MD, chief executive officer of Tennessee Oncology, offers his reaction to CMS' proposal to ease restrictions on how Part D managed the 6 protected classes of drugs.

Transcript

How will CMS’ proposal to ease restrictions on how Part D manages the 6 protected classes of drugs impact community oncologists and their patients?

Step edits in general are becoming very onerous. We have to hire staff, we have to have extra inventory, and we follow clinical guidelines, so we’re doing evidence-based medicine. So, they have to jump through these extra hoops and have other people tell us how care should be delivered is really onerous. We are not a fan of step edits in general, and not having excluded classes in Part D that were previously were, we’re not fans.

Related Videos
Virginia Kaklamani, MD | image credit: uthscsa.edu
dr parth rali
Dr Jeffrey Sippel
dr kimberly maxfield
dr april armstrong
Amal Trivedi, MD
Amitkumar Mehta, MD
Related Content
© 2023 MJH Life Sciences
AJMC®
All rights reserved.